{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T14:14:34Z","timestamp":1778076874154,"version":"3.51.4"},"reference-count":32,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100020865","name":"Takeda Pharma Vertrieb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Octocog alfa and rurioctocog alfa pegol have demonstrated efficacy in the prevention and management of bleeding associated with hemophilia A (HA) in clinical trials. The German AHEAD study (DRKS00000556) was designed to provide real-world data over a long period to complement these studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To assess real-world long-term outcomes in patients with moderate\/severe HA receiving octocog alfa or rurioctocog alfa pegol in routine clinical practice<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Noninterventional, prospective, study conducted between 2010 and 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The primary endpoint was the incidence of hemophilia-affected joint arthropathy. Secondary endpoints included annualized bleeding rate and joint bleeding rate (ABR\/AJBR), and octocog alfa and rurioctocog alfa pegol consumption. Final data are presented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The analysis included 377 patients aged 1\u201380\u2009years who received octocog alfa (severe HA,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009309; moderate HA,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200968) and 99 patients aged \u2a7e12\u2009years who received rurioctocog alfa pegol (severe,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200982; moderate,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200917). Over 8\u2009years of follow-up, average Gilbert scores were maintained with prophylaxis. In patients with severe HA, median ABRs\/AJBRs were generally lower with prophylaxis versus on-demand treatment, whereas in moderate HA, bleeding rates were similar. Treatment-related adverse events (AEs) and serious treatment-related AEs were reported in 5.3% and 4.2% (35 events including hemorrhage, arthropathy, and factor FVIII (FVIII) inhibitor development) of patients receiving octocog alfa, respectively, and 5.1% and 4.0% of patients receiving rurioctocog alfa pegol, respectively. One previously treated patient receiving octocog alfa developed de novo FVIII inhibitors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These real-world data corroborate previous clinical trial and real-world data demonstrating the long-term effectiveness and safety of octocog alfa and rurioctocog alfa pegol in patients with HA. In patients with severe HA, octocog alfa prophylaxis was associated with reduced bleeding rates compared with on-demand therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>Deutsches Register Klinischer Studien (German Clinical Trials Register): DRKS00000556.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207261419337","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:51:34Z","timestamp":1777870294000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Final data from the German AHEAD study: effectiveness and safety of octocog alfa and rurioctocog alfa pegol for hemophilia A in a real-world setting"],"prefix":"10.1177","volume":"17","author":[{"given":"Robert","family":"Klamroth","sequence":"first","affiliation":[{"name":"Department for Internal Medicine, Vascular Medicine and Haemostaseology, Vivantes Klinikum im Friedrichshain, Landsberger Allee 49, 10249 Berlin, Germany"},{"name":"Institute for Experimental Hematology and Transfusion Medicine, Bonn University Clinic, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5173-0896","authenticated-orcid":false,"given":"Karin","family":"Kurnik","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Pediatric Haemophilia Center, Dr. von Hauner Children\u2019s Hospital, LMU University Hospital Munich, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swee","family":"Wenning","sequence":"additional","affiliation":[{"name":"SRH Kurpfalzkrankenhaus, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0802-5280","authenticated-orcid":false,"given":"Carmen","family":"Escuriola-Ettingshausen","sequence":"additional","affiliation":[{"name":"H\u00e4mophilie-Zentrum Rhein Main GmbH, Frankfurt\/Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7730-0188","authenticated-orcid":false,"given":"Stephan","family":"Regensburger","sequence":"additional","affiliation":[{"name":"Takeda Pharma Vertrieb GmbH &amp; Co. KG, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leilei","family":"Tang","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Gu","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randy","family":"Guerra","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"Institute for Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,5,3]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1354422"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S304597"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720966888"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2024.2396617"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12438"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13270"},{"key":"e_1_3_4_9_2","unstructured":"German Medical Association (Bunders\u00e4rtztekammer). Cross-sectional guidelines for therapy with blood components and plasma derivatives (5th ed.) [publication in German] https:\/\/www.bundesaerztekammer.de\/fileadmin\/user_upload\/downloads\/pdf-Ordner\/MuE\/Querschnitts-Leitlinien_BAEK_zur_Therapie_mit_Blutkomponenten_und_Plasmaderivaten-Gesamtnovelle_2020.pdf (2020 accessed 13 January 2022)."},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005673"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-630897"},{"key":"e_1_3_4_12_2","first-page":"555","article-title":"Anti-hemophilic factor (recombinant), plasma\/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A","volume":"3","author":"Shapiro AD.","year":"2007","unstructured":"Shapiro AD. Anti-hemophilic factor (recombinant), plasma\/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A. Vasc Health Risk Manag 2007; 3: 555\u2013565.","journal-title":"Vasc Health Risk Manag"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14052"},{"key":"e_1_3_4_14_2","unstructured":"Baxalta Innovations GmBH. ADYNOVI Summary of product characteristics https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adynovi-epar-product-information_en.pdf (2023 accessed 8 February 2023)."},{"key":"e_1_3_4_15_2","unstructured":"Takeda Manufacturing Austria AG. ADVATE Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/advate-epar-product-information_en.pdf. (2023 accessed 8 February 2023)."},{"issue":"3","key":"e_1_3_4_16_2","first-page":"3","article-title":"Prophylaxis: musculoskeletal evaluation","volume":"30","author":"Gilbert MS.","year":"1993","unstructured":"Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol 1993; 30(3 Suppl 2): 3\u20136.","journal-title":"Semin Hematol"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04611.x"},{"key":"e_1_3_4_18_2","first-page":"15","article-title":"OR07: Optimizing prophylaxis: development of an advate PK calculator and dosing medical device based on a bayesian population PK model [abstract]","volume":"20","author":"Reininger A","year":"2014","unstructured":"Reininger A, Spotts G, L\u00f6w-Baselli A, et al. OR07: Optimizing prophylaxis: development of an advate PK calculator and dosing medical device based on a bayesian population PK model [abstract]. Haemophilia 2014; 20(Suppl 2): 15.","journal-title":"Haemophilia"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.2196\/resprot.6559"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-012-0020-y"},{"key":"e_1_3_4_21_2","first-page":"87","article-title":"P115: AHEAD international and German studies: 6-year interim effectiveness and safety outcomes in patients with hemophilia A receiving antihemophilic factor (recombinant) in a real-world setting [abstract]","volume":"26","author":"Oldenburg J","year":"2020","unstructured":"Oldenburg J, Ozelo MC, Klamroth R, et al. P115: AHEAD international and German studies: 6-year interim effectiveness and safety outcomes in patients with hemophilia A receiving antihemophilic factor (recombinant) in a real-world setting [abstract]. Haemophilia 2020; 26(Suppl 2): 87.","journal-title":"Haemophilia"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139873"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231218624"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712590902729392"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14282"},{"key":"e_1_3_4_26_2","first-page":"152","article-title":"Physical activity improved by adherence to prophylaxis in an Italian population of children, adolescents and adults with severe haemophilia A: the SHAPE Study","volume":"18","author":"Zanon E","year":"2020","unstructured":"Zanon E, Tagliaferri A, Pasca S, et al. Physical activity improved by adherence to prophylaxis in an Italian population of children, adolescents and adults with severe haemophilia A: the SHAPE Study. Blood Transfus 2020; 18: 152\u2013158.","journal-title":"Blood Transfus"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01837.x"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02539.x"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13616"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14201"},{"key":"e_1_3_4_31_2","first-page":"492","article-title":"A retrospective observational study of rurioctocog alfa pegol in clinical practice in the United States","volume":"26","author":"Aledort L","year":"2020","unstructured":"Aledort L, Milligan S, Watt M, et al. A retrospective observational study of rurioctocog alfa pegol in clinical practice in the United States. J Manag Care Spec Pharm 2020; 26: 492\u2013503.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_4_32_2","first-page":"449","article-title":"PB0594: Years of prophylaxis with rFVIII-Fc in haemophilia in a Portuguese haemophilia center: did doctors and patients see a change? [abstract]","volume":"5","author":"Campani\u00e7o S","year":"2021","unstructured":"Campani\u00e7o S, Rodrigues F, Pereira A, et al. PB0594: Years of prophylaxis with rFVIII-Fc in haemophilia in a Portuguese haemophilia center: did doctors and patients see a change? [abstract]. Res Pract Thromb Haemost 2021; 5(Suppl 2): 449.","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_3_4_33_2","first-page":"63","article-title":"P0073: A within-patient and matched-pair comparison of real-world outcomes in patients using rFVIII and rFVIIIFc prophylaxis, in the UK [abstract]","volume":"26","author":"Scott M","year":"2020","unstructured":"Scott M, Wall C, Xiang H, et al. P0073: A within-patient and matched-pair comparison of real-world outcomes in patients using rFVIII and rFVIIIFc prophylaxis, in the UK [abstract]. Haemophilia 2020; 26(Suppl 2): 63.","journal-title":"Haemophilia"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261419337","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207261419337","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261419337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T13:17:31Z","timestamp":1778073451000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207261419337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":32,"alternative-id":["10.1177\/20406207261419337"],"URL":"https:\/\/doi.org\/10.1177\/20406207261419337","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"article-number":"20406207261419337"}}